Teva launches generic Solodyn
Teva has introduced its generic Solodyn (minocycline HCl). The drug is indicated to treat inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients ages 12 years and older.
Teva’s generic Solodyn will be available in 65- and 115-mg dosage strengths.
“The launch of these two strengths of our generic version of Solodyn brings an effective, affordable treatment option to patients who are managing this condition, and marks our ninth generic medicine in the tetracycline category,” Teva executive vice president and head of North American commercial Brendan O’Grady said.
The product had U.S. sales of roughly $148 million for the 12 months ended December 2017, according to IQVIA data.
Teva’s generic Solodyn will be available in 65- and 115-mg dosage strengths.
“The launch of these two strengths of our generic version of Solodyn brings an effective, affordable treatment option to patients who are managing this condition, and marks our ninth generic medicine in the tetracycline category,” Teva executive vice president and head of North American commercial Brendan O’Grady said.
The product had U.S. sales of roughly $148 million for the 12 months ended December 2017, according to IQVIA data.